[ad_1]
Denmark pauses the AstraZeneca corona vaccination vaccine after a death, the Danish Ministry of Health writes in a press release.
The reason is that several have been reported to have had severe cases of blood clots, they write.
The pause takes place with immediate effect and lasts basically 14 days. So far, a clear connection between the vaccine and blood clots has not been shown.
– I need to answer
– It is not an easy decision to pause one of the vaccines, but it is precisely because we vaccinate so many that we have to react with caution, when we are warned of possible serious side effects. So we have to clear it up, before we can continue to use the AstraZeneca vaccine, writes director Søren Brostrøm at the Danish Ministry of Health.
Danish authorities emphasize that they have not ruled out the vaccine.
– Importantly, we have not ruled out the AstraZeneca vaccine, rather we have put it on hold. There is good evidence that the vaccine is safe and effective, but both we and the Norwegian Medicines Agency have to respond to reports of possible serious side effects, both from Denmark and other European countries. Show that the monitoring system works, Bostrøm writes.
NIPH: significantly inhibits infection
– Supplied
The Norwegian Institute of Public Health (FHI) writes on Twitter that they have been informed of the Danes’ decision.
– FHI is in dialogue with the Norwegian Medicines Agency to clarify the situation and will return when we have more information, writes FHI.
FHI informs Dagbladet that they will be coming with more information soon.
Dagbladet has also tried to get comment from both the Health Ministry and AstraZeneca, so far without success.
Urgent meeting
The Norwegian Medicines Agency’s chief physician, Sigurd Hortemo, tells Dagbladet that they now have meetings.
– We will have a meeting with FHI at 11:00 am. What we can say is that we are aware that some cases of blood clots have been reported among young people in Austria, Denmark and other countries. But a definitive connection to the vaccine has not yet been determined, says chief physician Sigurd Hortemo of Dagbladet’s Norwegian Medicines Agency.
– This will be investigated carefully. Denmark has chosen to stop using the vaccine while it is in progress. The Norwegian Medicines Agency and the NIPH will assess whether this is also relevant in Norway.
Health personnel
It is mainly health professionals who have received doses of AstraZeneca in Norway.
The Norwegian Nurses Association (NSF) tells Dagbladet that this shows that the systems work.
Eliminate vaccine confusion
– This shows that quality assurance systems work. When there are warnings of serious side effects, regardless of the medication, it should be clarified if it is really related to vaccines in this case or is it accidental information. NSF is awaiting FHI assessment, says union leader Lill Sverresdatter Larsen
Extended approval
The AstraZeneca vaccine was originally approved for use in people between the ages of 18 and 65. This was recently changed in several countries, where the vaccine was approved for use by people over 65 as well.
The vaccine was approved for use in the EU in late January.
